Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.

Genco, C., Cabibbo, G., Maida, M., Brancatelli, G., Galia, M., Alessi, N., et al. (2013). Treatment of hepatocellular carcinoma: present and future. EXPERT REVIEW OF ANTICANCER THERAPY, 13 [10.1586/era.13.21].

Treatment of hepatocellular carcinoma: present and future.

GENCO, Chiara;CABIBBO, Giuseppe;MAIDA, Marcello Fabio;BRANCATELLI, Giuseppe;GALIA, Massimo;BUTERA, Giuseppe;RAINERI, Santi Maurizio;GIARRATANO, Antonino;MIDIRI, Massimo;CAMMA', Calogero
2013

Abstract

Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.
Genco, C., Cabibbo, G., Maida, M., Brancatelli, G., Galia, M., Alessi, N., et al. (2013). Treatment of hepatocellular carcinoma: present and future. EXPERT REVIEW OF ANTICANCER THERAPY, 13 [10.1586/era.13.21].
File in questo prodotto:
File Dimensione Formato  
Genco, Cabibbo et al ERAT 2013.pdf

Solo gestori archvio

Dimensione 675.25 kB
Formato Adobe PDF
675.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/74498
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 24
social impact